Trials / Recruiting
RecruitingNCT05985161
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
A Multi-Center Phase II Study of Selinexor in Treating Recurrent or Refractory Wilms Tumor and Other Pediatric Solid Tumors
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 12 Months
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Conditions
- Wilms Tumor
- Rhabdoid Tumor
- Malignant Peripheral Nerve Sheath Tumors
- MPNST
- Nephroblastoma
- XPO1 Gene Mutation
- Solid Tumor
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | This phase II study will initially treat all patients, including adult patients, at the pediatric Selinexor RP2D of 35 mg/m2 (no maximum dose) once weekly using a liquid suspension . |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
- First posted
- 2023-08-14
- Last updated
- 2025-11-26
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05985161. Inclusion in this directory is not an endorsement.